PetVivo Reports Reports Fiscal Q1 2025 Results

Core Viewpoint - PetVivo Holdings, Inc. is experiencing growth in revenue and operational milestones, driven by the adoption of its flagship product, Spryng with OsteoCushion technology, and is reiterating its revenue guidance for fiscal 2025, expecting a growth of 50% to 100% compared to the previous year [1][13]. Financial Highlights - Revenues for fiscal Q1 2025 increased by 6% to $124,000, attributed to the rollout of Spryng [3][14]. - Sales to distributors surged by 102% to $68,000, indicating strong demand and expansion of the distributor network [3]. - Gross profit rose by 6% to $111,000, maintaining a gross margin of 89.5% [3][14]. - The net loss improved to $2.0 million or $(0.11) per share, compared to a net loss of $2.9 million or $(0.25) per share in the same quarter last year, due to cost-reduction strategies [3][16]. Operational Highlights - Spryng is now distributed in over 800 veterinary clinics across all 50 states, with more than 10,000 syringes sold [4]. - Key appointments include April Boyce as VP of Marketing and Bryan Monninger as VP of Sales, both bringing extensive experience from major companies [4][8]. - The company showcased Spryng at significant veterinary conferences, enhancing its visibility among industry experts [4][12]. Strategic Outlook - The company plans to accelerate market adoption of Spryng through additional key hires and strengthening its sales and marketing teams [7][9]. - Ongoing clinical studies, including one at Colorado State University, are expected to bolster the product's credibility and support distribution strategies [10][11]. - PetVivo is positioned to capitalize on the growing $5.7 billion U.S. animal health market, projected to reach $11.3 billion by 2030 [13]. Revenue Guidance - For fiscal 2025, the company anticipates net revenue between $1.5 million and $2.0 million, reflecting a growth of approximately 50% to 100% over the prior year [13].